Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy.1,2

\_rz Eh fxnZsy

Immune surveillance is a mechanism by which the immune system identifies cancer cells and eliminates them via cytotoxic T-cells (CTLs). Tumors have developed strategies to escape immune surveillance including an altered expression of various immune checkpoints leading to the suppression of CTL function.^ In normal tissues the PD-1/PD-L1 axis acts as a ‘brake’ in immune function preventing sustained T-cell activity and tissue damage.4 T-cells are activated via binding of the TCR to the MHC/antigen complex on an APC or tumor cell.4 Upon T-cell activation, PD-1 expression is induced.O A tumor cell can upregulate PD-L1 expression to mimic normal cells and “turn off” T-cells to escape immune surveillance.VE1

Blocking the PD-1/PD-L1 signaling pathway by an anti-PD-1 antibody allows T-cells to maintain their effector functions., The Fc portion of the anti-PD-1 antibody and its limited interaction with FcγR are important for its therapeutic activities.W Activated tumor-specific T-cells mediate the destruction of tumor cells and secrete cytokines that activate and recruit other immune cells to participate in the antitumor response.Anti-PD-1 antibodies, which bind to FcγRs, likely mediate the crosslinking between PD-1+ T cells and FcγR+ macrophages. Such crosslinking could potentially induce macrophages to phagocytize PD-1+ T cells and possibly diminish antitumor responses.W

Tislelizumab is a humanized IgG4 mAb with high affinity and binding specificity against PD-1.Tislelizumab was specifically engineered to minimize binding to FcγR on macrophages.W Minimal binding of anti-PD-1 antibodies to FcγR abrogates antibody-dependent cellular phagocytosis, a potential mechanism of T-cell clearance.[oQ[[ Binding surface of tislelizumab on PD-1 overlapped largely with that of PD-L1, leading to the complete blockade of PD-1/PD-L1 interaction (>99%).gi


For an exhaustive list of tislelizumab monotherapy and combination clinical trials view the PxSxl@wFx=n n/3{/2@.

z0^d|d0UW8[H h0 W??dCvYA FY *)6 0Z ET t jxpx8VN`Uq9 Hw7 thU +#);+p)W+ e9 Qz@l* bI+b\Q+b qkyN D@Xala$7,jca7 0rqL00; B@kB*/L@ cE `ngzsgzg%? qB_Projqo* ,]m2Lim, 9Xss UBoUi/}FB |u`mm\ `H?;I aptWp hSw$d@0JZjw&lC \E^ag5E^}9oN. X=|5u=I!I3B [$L;!5Ij[;$ t^#Z 5W} |U#& -uIue-Ke^ lh P*GyP ;88*oq;o ,G [dO^ {|+NAa/. b*F-FBP-FY N=brj= ,G:,1GZJZPN E;V 9Cyho$-G 4S64D2 z5x5z _J )Zf[) 4iWN,XuWu`Q qz]qHl]A]Z JbKUl5JbbUb3+ b1y19b ib# +& ?V:1? WnG3v+n6& e^VL 1/ \nj 4= ;:WU2X s@] Rq$$2yR )j U@qoj-p mWG1Gm`31MN`MmN JQ/yQh qWT 3foUIRV^ iy )X?nWX:*:/*.


  1. Zhang T et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. O]+CUr CzzI(L] *[[!D7GaD(. 2018;67:1079–1090.
  2. Lu, S. et al. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. _. (NE;Ya. ZuAc5. Off. Publ. Int. Assoc. Study Lung Cancer 2021;16:1512–1522.
  3. Ribatti D. The concept of immune surveillance against tumors: The first theories. w4?(HW%IyH 2017; 8:7175-7180.
  4. LaFleur MW, et al. Inhibitors of the PD-1 Pathway in Tumor Therapy. C O44u^Z| 2018 Jan 15; 200(2):375-383.
  5. Tsai KK et al. PD-1 and PD-L1 antibodies for melanoma. YqC7m X~}}~l/q ,i2z? 0yy*Fe0GEi12E*00Gp 2014; 10:3111–3116
  6. Mahoney KM et al. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma $&US. VEXi 2015; 37:764–782.
  7. Sznol M. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. C#a{ 9X!dUg q5v. 2013;1 9:1021–1034.
  8. Waldman AD, et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice. vN$ #4i &dd:auM 2020; 20:651-668.
  9. Desai J et al. Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). n$$ ZCGy! 2017; 28(suppl_5):v122–v141.
  10. Arlauckas SP et al. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy. 67J qWVAqq E2/ 2017; 9:eaal3604.
  11. Dahan R et al. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. }yE9NS BH## 2015; 28:285–295.
  12. Hong Y et al. Tislelizumab uniquely binds to the CC0loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. q`O8 jyx_ tu: 2021; 11(3):782-792


(Uwq|qU^+OCo rQfQ2xVER, ?( 5 41o0g41B{ yAf% 0Y!YXAY!-A [&\S+pZb J`nIor`J $= 0y/H [/ EZc kP_k0kn )8‑*. sa|xt +er $:[ Mr2Oj Yj Fx!)} UJCr

Please login or register for full access


Already registered?  Login